Impact of Antiepileptic Drugs on HIV Treatment Outcomes
Author Information
Author(s): Okulicz Jason F, Grandits Greg A, French Jacqueline A, George Jomy M, Simpson David M, Birbeck Gretchen L, Ganesan Anuradha, Weintrob Amy C, Crum-Cianflone Nancy, Lalani Tahaniyat, Landrum Michael L
Primary Institution: Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences
Hypothesis
Does the use of cytochrome P450 enzyme-inducing antiepileptics affect the efficacy of highly-active antiretroviral therapy (HAART) in HIV-infected individuals?
Conclusion
The use of enzyme-inducing antiepileptics is associated with a higher risk of virologic failure in patients receiving HAART.
Supporting Evidence
- 62.5% of EI-AED participants experienced virologic failure compared to 26.7% in the NEI-AED group.
- Virologic failure was significantly higher in the EI-AED group across multiple HAART/AED overlap periods.
- Participants on EI-AEDs had a higher average viral load during treatment compared to those on NEI-AEDs.
Takeaway
If people with HIV take certain seizure medications, their HIV treatment might not work as well, which can lead to more health problems.
Methodology
This study analyzed virologic outcomes in HIV patients on HAART who were also taking enzyme-inducing antiepileptics, comparing them to those on non-enzyme-inducing antiepileptics and those not on any AEDs.
Potential Biases
Potential biases include differences in treatment experience and underlying health conditions among groups.
Limitations
The study had a small sample size and may not account for all variables affecting virologic outcomes.
Participant Demographics
Participants were primarily military members with HIV, with a mean age of 40.1 years in the EI-AED group.
Statistical Information
P-Value
0.009
Confidence Interval
OR 4.58 [1.47-14.25]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website